https://orcid.org/0000-0002-3503-5778
References
- Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018; 14(5):270–284.
- Brutocao C, Zaiem F, Alsawas M, et al. Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018; 62(2):318–325.
- Matevosyan NR. Schizophrenia and Stein-Leventhal syndrome: comorbidity features. Arch Gynecol Obstet. 2011; 284(4):1035–1041.
- Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1(1):15067.
- Matsunaga H, Sarai M. Elevated serum LH and androgens in affective disorder related to the menstrual cycle: with reference to polycystic ovary syndrome. Psychiatry Clin Neurosci. 1993;47(4):825–842.
- Cesta CE, Mansson M, Palm C, et al. Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort. Psychoneuroendocrinology. 2016;73:196–203.
- Hung JH, Hu LY, Tsai SJ, et al. Risk of psychiatric disorders following polycystic ovary syndrome: a nationwide population-based cohort study. PLoS One. 2014;9(5):e97041.
- Berni TR, Morgan CL, Berni ER, et al. Polycystic ovary syndrome is associated with adverse mental health and neurodevelopmental outcomes. J Clin Endocrinol Metab. 2018;103(6):2116–2125.
- Oyffe I, Lerner A, Isaacs G, et al. Clomiphene-induced psychosis. Am J Psychiatry. 1997;154(8):1169–1170.
- Cheng HY, Ko KT, Tzang RF. Metformin-induced first-episode psychosis in patient with polycystic ovary syndrome using drospirenone. Psychiatry Clin Neurosci. 2019;73(4):196–196.
- Hsieh CY, Su CC, Shao SC, et al. Taiwan’s National Health Insurance Research Database: past and future. CLEP. 2019;11:349–358.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
- Nilssen Y, Strand TE, Wiik R, et al. Utilizing national patient-register data to control for comorbidity in prognostic studies. Clin Epidemiol. 2014;6:395–404.
- Thygesen SK, Christiansen CF, Christensen S, et al. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11(1):83.
- Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1–13.
- Kohler-Forsberg O, Sorensen HJ, Benros ME, et al. Association between prior somatic disease and 5-year relapse risk among 11,856 incident patients with schizophrenia. Eur Psychiatr . 2019;59:1–7.
- Gogos A, Sbisa AM, Sun J, et al. A role for estrogen in schizophrenia: clinical and preclinical findings. Int J Endocrinol. 2015;2015:1–16.
- Kopala LC, Lewine R, Good KP, et al. Clinical features of schizophrenia in a woman with hyperandrogenism. J Psychiatry Neurosci. 1997;22(1):56–60.
- Carvalho LML, Dos Reis FM, Candido AL, et al. Polycystic ovary syndrome as a systemic disease with multiple molecular pathways: a narrative review. Endocr Regul. 2018;52(4):208–221.
- Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–741.
- Eggers S, Kirchengast S. The polycystic ovary syndrome-a medical condition but also an important psychosocial problem. Coll Antropol. 2001; 25(2):673–685.
- Ajmal N, Khan SZ, Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article. Eur J Obstet Gynecol Reprod Biol X. 2019;3:100060.